Altimmune, Inc.

Altimmune, Inc. Earnings Recaps

ALT Health Care 3 recaps
Q1 2026 May 14, 2026

Altimmune's shares declined 1.9% following Q1 results as the market digested ongoing progress on pipeline development but showed caution given the lack of new catalytic data and the company’s still-early clinical stage profile.

Key takeaways
  • Completed an oversubscribed $225 million public offering in April, bringing cash balance to approximately $535 million, securing funding through Phase III MASH 52-week readout expected in 2027.
  • Preparing to initiate global Phase III PERFORMA study for pemvidutide in MASH in H2 2026, with finalized protocol aligned with FDA and EMA feedback.
  • Anticipated top-line data from Phase II AUD trial next quarter; enrollment in ALD RESTORE trial expected to complete in Q3 2026.
  • No new clinical efficacy or safety data disclosed this quarter; update primarily focused on trial preparations, regulatory alignment, and financing.
  • Market reaction suggests investors remain cautious, reflecting execution risk and absence of near-term catalysts beyond trial initiation.
Full recap
Q3 2025 Nov 6, 2025

Altimmune reported strong progress in its clinical programs for pemvidutide, positioning itself at a pivotal juncture with upcoming data readouts and regulatory meetings that could accelerate its growth in treating liver diseases.

Key takeaways
  • Anticipating Q4 disclosure of 48-week IMPACT trial data, building on positive 24-week results showcasing rapid efficacy in liver disease treatment.
  • Secured in-person end of Phase II meeting with the FDA to discuss Phase III trial design, emphasizing an alignment with regulatory expectations.
  • Completed enrollment ahead of schedule in the RECLAIM Phase II trial for alcohol use disorder, reflecting strong interest and operational efficiency.
  • Expanded leadership team with key appointments to drive future clinical and commercial strategies.
Full recap
Q2 2025 Aug 12, 2025

Altimmune reported positive second-quarter results, showcasing pembiguate's statistical success in NASH trial endpoints, reinforcing its potential pipeline and solidifying its financial position with $183.1 million in cash reserves.

Key takeaways
  • Pembiguate achieved statistical significance in NASH resolution and key efficacy measures during the IMPACT trial's 24-week period.
  • The company has initiated Phase II trials for alcohol use disorder (AUD) and alcohol-associated liver diseases (ALD) with famidutide.
  • Jerry Durso has been appointed as Chairman, a strategic move to guide the transition to Phase III development for pembidutide.
  • Altimmune's impressive cash position enables continued advancement of clinical programs and strategic initiatives.
  • Pemvigutide demonstrated favorable safety and tolerability profiles, enhancing its competitiveness among NASH therapies.
Full recap